Clinical Trial

Clinical Study of G Protein Biased Μ - Opioid Receptor Agonist Oliceridine for Optimizing Postoperative Analgesia Under General Anesthesia

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 31, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
Traditional opioid analgesia is a treatment method for moderate to severe pain. However, the use of opioid drugs is not without risks. When treating acute pain, patients may experience hypotension, respiratory depression, hypoxia, nausea and vomiting, irritability, and itching. The purpose of this study is to evaluate the comparison of G protein biased μ - opioid receptor agonist oliceridine and traditional μ - opioid receptor agonist sufentanil in terms of analgesia in patients under general anesthesia.
Trial Details
NCT Number NCT06668298
Lead Sponsor Henan Provincial People's Hospital
Conditions Old Age
Enrollment 150 participants
Start Date 2024-11
Primary Completion 2025-06 (estimated)
Study Completion 2025-06 (estimated)
Updated on ClinicalTrials.gov 2024-10-31